RxDoctor Payments Data

Mark McClintock, OD

Optometrist · Birmingham, ALNPI 1750384202

Payments from drug & device makers

$3,531in general payments, 2019–2025

Across 142 payments — averaging $24.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$1K
  • Bausch & Lomb Americas Inc.$717
  • AbbVie$372
  • NEW World Medical,inc.$307
  • Glaukos Corporation$299
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$218
  • plus $509 from 12 others

What the payments were for

  • Food & beverage$3,531100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,531 in reported general payments places this provider in the 85th percentile of 749 optometrist providers in Alabama.

See all optometrist providers in Alabama

Medicare billing

Part B allowed, 2024
$127,659
Medicare patients
675
Services billed
1,610

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine27$35,371
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat602$15,333
Cyclosporine20$14,221
MieboPerfluorohexyloctane/Pf17$12,393
CombiganBrimonidine Tartrate/Timolol14$10,723
Fluorometholone167$10,274
Latanoprost575$10,144
Brimonidine Tartrate202$7,741
VyzultaLatanoprostene Bunod13$5,979
Prednisolone Acetate143$5,655
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol37$5,228
Travoprost11$3,229
ValacyclovirValacyclovir Hcl38$1,757
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha111$1,564
Dorzolamide Hcl40$1,271

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Combigan$372$46,09441 claims
Bausch & Lomb Americas Inc.Miebo, Vyzulta$717$18,37230 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 749 optometrist providers in Alabama.

Other optometrist in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →